Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study-Reference-Cited by-同舟云学术

Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Published:2019-08-13 Issue:1 Volume:61 Page:98-107
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cortes Jorge¹,Huynh Lynn²,Mendelson Estella³,Brandt Patricia³,Dalal Darshan³,DerSarkissian Maral²,Cortina Diego³,Narkhede Sahil¹,Sheng Duh Mei²

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

2. Analysis Group, Inc., Boston, MA, USA;

3. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1644332

Reference38 articles.

1. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia

2. Chronic Myeloid Leukemia: Diagnosis and Treatment

3. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-04

2. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

3. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

4. Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia;International Journal of Hematologic Oncology;2022-06

5. Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review;European Journal of Haematology;2022-05-24